Medical radiotherapy has traditionally relied upon the use of external photon beams and internally implanted radioisotopes as the chief means of irradiating tumors. Howewr, advances in accelerator technology and the exploitation of novel means of producing radiation may provide usehl alternatives to some current modes of medical radiation delivery -with reduced total dose to surrounding healthy tissue, reduced expense, or increased treatment accessibility. This paper will briefly overview currently established modes of radiation therapy, techniques still considered experimental but in clinical use, innovative concepts under study that may enable new forms of treatment or enhance existing ones. The potential role of low energy, ion-induced nuclear reactions in radiotherapy applications is examined specifically for the 650 keV d(3He,p)4He nuclear reaction. This examination will describe the basic physics associated with this reaction's production of 17.4 MeV protons and the processes used to fabricate the necessary materials used in the technique. Calculations of the delivered radiation dose, heat generation, and required exposure times are presented. Experimental data is also presented validating the dose calculations. The design of small, lower cost ion accelerators, as embodied in 'nested'-tandem and radio frequency quadrupole accelerators is examined, as is the potential use of high-output 'He and deuterium ion sources. Finally, potential clinical applications are discussed in terrns of the advantages and disadvantages of this technique with respe-ct to current-radiotherw-methods and equipment.
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Background
Ideally, the aim of medical radiation therapy is to deliver a lethal dose of radiation to a clearly defmed region of diseased tissue while inflicting little or no radiation damage on surrounding healthy tissue.
However, the delivery of radiation to the diseased tissue almost always involves transport of the incident radiation across healthy tissue. It has been stated in the medical literature that, 'I... large tumors are less likely to be cured at doses of radiation that are still within the tolerance of adjacent normal tissue. Normal tissue sparing is enhanced when (a) the volume of irradiated normal tissue is reduced and @) the biologic effect on tumor cells is greater than that on surrounding normal cells. These two factors must be optimized to improve the probability of an uncomplicated cure" [I] .
The most widely accepted and utilized form of radiation treatment is external beam radiotherapy.
This term applies to the use of x-rays or gamma rays to deposit energy at the site of a tumor. Beams of xrays are usually produced by linear electron accelerators or x-ray tubes, while the decay of elements such as radium, uranium or cobalt-60 serve as sources of gamma radiation. The depth of irradiation is controlled through the setting of the x-ray beam energy or selection of the gamma ray source. As illustrated in figure 1, significant damage is delivered over the entire length of the radiation's path.
Controlling the balance between the,damage delivered to the tumor and that done to intervening healthy tissue is critical in performing the therapy. Exploiting what is termed the dose-response effect, (i.e. the ability of healthy cells to recover from radiation damage more quickly than cancerous cells), repeated exposures at sub-lethal doses are delivered to both the tumor and the surrounding healthy tissue in a timed sequence such that, owing to the dose-response effect, the accumulated damage at the tumor exceeds that of the healthy tissue. Thus, although the radiation is broadly delivered, the damage induced is more localized owing to the differences in recovery times of the exposed tissues.
A higher degree of damage localization is often achieved through the use of radioactive implants, a treatment called internal radiotherapy. Specific clinical procedures based upon this concept are referred to * as brachytherapy, interstitial irradiation, and intracavitary irradiation. In this procedure, radioisotopes are physically inserted at the site of the tumor. The irradiated volume depends upon the range of the decay products of the implanted radioisotopes and the size of the region over which the material is implanted.
This procedure most often requires the patient to remain in the hospital for 2he length of the treatment, normally a few days, until the implanted radioisotopes are removed.
.
One new technique being explored in radiation therapy is intra-operative irradiation; in this procedure, the site of the surgically removed tumor and the surrounding tissue are irradiated with a large dose of external radiation while exposed during surgery. In this way, isolated cancer cells still remaining after removal of the main body of the tumor, are killed in situ. One problem with this technique resides in the common need to transport the patient from the sterilized environment of' the surgical theater to the radiation facilities of the hospital. A suitably compact radiation source for hoperating room irradiation would greatly facilitate this technique. , proton radiotherapy exploits the enhanced energy deposition manifest at the end of range of energetic ion beams (i.e. the Bragg peak) as a means of preferentially depositing energy at a tumor site. In practice, synchrotron-or cyclotron-produced high energy proton beams, with energies of 50 to 250 MeV, are precisely targeted into the immobilized patient along an incident path selected to minimize damage to intervening sensitive organs or tissue. The energy of the incident beam is selected so that the protons come to rest at or near the tumor. Variations in the depth of penetration are accomplished using devices called "phantoms" or boluses which tailor the range of the initially monoenergetic incident beam before it enters the patient. As shown in figure 1, the damage done along the incident path of the beam can be as little as 30% of that delivered to the site of the tumor.
However, even with this reduction in dose to healthy tissue, the incidental radiation damage limits the deliverable dose for any single exposure and often requires the use of either multiple incident paths in a single radiation treatment, or fiactionated treatments at sub-lethal doses over multiple sessions, again relying on differing dose-response effects. Proton radiotherapy requires precise radiation transport and targeting calculations, and also the ability to maintain rigid control of the patient's position and/or the incident beam trajectory during treatment.
Even higher localization of irradiation is attempted with a technique callecl Neutron Capture Therapy, first proposed in the 1930s [4] . Boron neutron capture therapy (BNCT) involves the selective inkoduction * of boron-IO to a tumor site, via administration of chemically tailored 'OB-containing compounds which preferentially bind to tumor cells. Once the tumor is "doped" with boron-10, the patient is exposed, either intra-operatively or externally, to thermal (<lev> or epithermal (lev -10 keV) neutrons. These neutrons have only modest interaction with the surrounding boron-free, healthy tissue, but can induce the I0B(n,cc)'Li nuclear reaction in the 'OB-doped tumor. This reaction produces lithium and helium fission fragments with a shared energy of 2.3 MeV, and a range in tissue of approximately 10 microns; this is comparable to the dimension of a single mammalian cell. Thus, localization of damage is achieved by producing the most damaging radiation at the site of the tumor and the spatial extent of the damage is controlled by the range of the reaction products.
Other research has combined chemical and radiological effects through use of radiosensitizer drugs, which enhance a tumor's susceptibility to radiation damage, and radioprotectors that conversely increase the radiation tolerance of normal tissue. Related radiobiological effects based upon thermal changes in radiosensitivity (hypothermia), and the oxygen-dependence of radiation damage (hypoxia), are also being investigated for their potential in selectively altering the susceptibility of tissue to radiation. Radiation exposures introduced even at the molecular level are being studied via the use of radiolabeled antibodies which preferentially deliver radiation to the tumor in a technique termed radioimmunotherapy.
Introduction
The continuing trend in the development and enhancement of radiation therapy techniques is toward greater spatial control of the induced damage around tumors and reduced exposure of healthy tissue.
Convoluted with this clear clinical objective, however, are the pragmatic constraints imposed by the need for any new techniques or equipment to be more effective, affordable, accessible, and produce less medical waste than current techniques. Within this framework, we present a description of a new concept for the production and delivery of energetic protons for use in radiotherapy; it is based upon the fact that low energy, ion-induced nuclear reactions can produce highly energetic radiation products suitable for use in tumor irradiation. By employing specially fabricated needles as evacuated conduits to deliver beams of energetic ions to selected target materials sealing the end of the needle, ion beam-induced nuclear reactions can be generated at the needle tip which emit reaction-specific radiation products.
The d(3He,p)4He nuclear reaction produces energetic protons suitable for radiotherapy applications.
In this reaction, the collision of a 650 keV 3He nucleus with a deuterium nucleus can result in a nuclear reaction which produces 4He, and a proton with energies that vary from 13. Two separate implementations of the ion-induced nuclear radiotherapy (hereafter referred to as . INRT) concept are shown schematically in Figure 2 . In its internal usage, which we will refer to as pINRT, the needle tip is used to produce a point-source of radiation at the tumor site. In this mode, which is analogous to a switchable, intensity-adjustable form of brachytherapy, it is envisioned that the MRTneedle is inserted to the site of a tumor in the same manner that a biopsy needh: is inserted into a patient to sample the tumor. Once positioned, the axis of the incident low energy ion beam and the insertion vector of the MRT needle are made coincident by adjusting electrostatic steering of the low energy ion beam or by re-orienting the entire accelerator assembly on its own three-axis frame; two types of compact, lightweight (several hundred pound) accelerators suitable for INRT are described later in this article. The ion beam is directed down the evacuated needle where it strikes the needle tip producing the radiation products. The radiation is confmed to a pre-determined region about the tip ofthe needle, defmed by the range of the reaction products in tissue. Since the INRT-needle delivers the low energy ion beam to the tumor site without any radiation damage to the surrounding tissue, the deliverable dose is not limited by incidental dose to healthy tissue.
In the external mode of usage, referred to as topical MRT (figure 2b), a broad swathe of radiation is produced by positioning the needle-tip some distance back from the exposed treatment surface; the intervening air gap permits the reaction products to spatially diverge with marginal energy loss before striking the larger target area. A simple Plexiglas shroud surrounding the external needle (tube) confines the radiation products to the intended exposure site and the area of irradiation is readily defmed through use of masking materials only millimeters thick.
Ion Induced Nuclear Radiotherapy
i. The 650 keV d(3He,p)4He Nuclear Reaction
The total yield of energetic protons from such an ion-induced nuclear reaction can be given in its simplest form, for a target of uniform deuterium concentration, as:
The number of incident ions, Ni, is usually measured in terms of the total electrical charge deposited on the target by the ion beam. For a beam of singly-ionized 3He ions, Ni is simply the total charge collected on target divided by the charge per ion ( 1 . 6~1 0 -l~ Coulombs). A 1 microCoulomb (pC) ion exposure therefore corresponds to Ni = 6 . 2 5~1 0~~ incident 3He nuclei.
C, is the deuterium concentration in the target, which is uniform in this case. Metal matrices such as titanium, zirconium, erbium and scandium have been shown to maintain stable hydrogen (and deuterium)
concentrations of 1 . 1 6~1 0~~ deuterium/cm3, or a stoichiometry of TiD,, for example [5] .
o Q , the reaction's energy-dependent total cross section, is reported for 3He energies up to.2.5 MeV
. by Muller and Besenbacher [6] . The cross section for this reaction is quite broad with a peak of 0.825 barn at about 650 keV. A slightly higher incident 3He energy of 800 keV is used hi order to increase the thick target proton yield from the reaction. o Q is converted to a depth-dependent ~( x ) by using the energydependent stopping power (dWdx) of the incident 'He ion in the target to convert the energy-dependence of the published cross section to a corresponding depth-dependence specific to the target and incident beam energy. The total integrated cross section for an 800 keV 3He ion in TiD2, over its fill range of 1.9 microns in TiD,, is 6 . 7~1 0 -~~ cm3.
The total yield of 17.4 MeV protons resulting from a 1pC exposure of a TiD2 MRT needle to an 800 keV 3He ion beam is then calculated to be, Y = 4.85~10' protons/pC 3He.
Since 17.4 MeV protons have a range of 3.1 millimeters in tissue [7] , the irradiated volume is 0.125 cm3. Applying the defmition of dose as "the amount of energy imparted to matter by ionizing particles per unit mass of irradiated material" [6] , the delivered radiation dose per 17.4 MeV proton to the 0.125 cm3 exposed volume of tissue, with a density of 1.0 g/cm3, is 2 . 2~1 0~~ raddproton. Multiplying this dose rate per proton by the number of protons produced per incident pC yields a total dose delivery rate of 108 rads/$.
Thus, a 1.0 microamp 3He ion beam directed onto a TiD2 INRT needle delivers roughly 100 rad/sec, or 1 Gy/sec, to the irradiated volume.
However, in order to include both the l/r2 dependence of the energy deposition and the end-of-range
Bragg peak in the proton dose deposition curve, a computer simulation of the proton energy loss through individual volume elements within the exposed volume was performed. This calculation uses a differential form for the radiation dose delivered by the protons: eq.4
This expression takes into account a small energy loss in the TiD, target foil. The stopping power, dE/dr, ' was determined by numerically differentiating eq. 2.
ii. pINRT Radiation Field For use ir! dermatological or intra-operative procedures, a broader, more uniform dose distribution can be achieved by displacing the MRT needle back from the target so as to allow the product radiation to diverge from the needle tip. Increasing the distance from the needle to the target is done at the cost of reduced dose rate, unless the incident ion beam current is raised to compensate for this by increasing the rate of radiation production. Since the topical MRT needle is not in physical contact with any tissue and the 'needle' diameter is large (1") allowing the power density to be moderated by increasing the beam spot diameter, the beam current can be increased to attain higher radiation output yields. Figure 2b displays a three dimensional rendering of the radiation pattern, in Grayhec, resulting from an INRT exposure using a 1 milliamp, 800 keV 3He ion beam incident on a TQ-tipped needle. The 1" diameter 'needle' is displaced from the target by 6". The volume element used in calculating the radiation dose is 100 microns on edge.
The baseline radiation doserate in this implementation is 0.1 Gylsec.
iv. Thermal Effects
The dissipation of heat produced by the incident 3He ion beam impacting the needle-end is also a concern in evaluating possible effects on surrounding healthy tissue. For the purpose of estimating the local temperature rise due to this technique, the heat transfer process is approximated by considering the treatment area as imbedded in a large mass with the same stoichiometry and thermal conductivity as muscle tissue. This, of course only applies to the pMRT application; in the topical treatment no needle ' contact with the tissue occurs so heating is irrelevant except for the target film's integrity. Heat, (corresponding to the stopping of a 1 FA 3He ion beam in the needle-end), is introduced continuously over a 100 second exposure time at the center of this volume and removed only by conduction through the medium. The temperature at the outer boundary of the irradiated volume would increase by approximately 12 OC during the 70 Gy exposure and decrease to less than a 5 OC elevation in temperature above ambient within 40 seconds after the end of the exposure. This conservative estimate assumes only a static thermal mass, and excludes heat removal by the INRT needle and the local circulatory system. The temperature increase above ambient, due to the radiation delivery is shown in figure 5 for positions 5mm and 3mm from the needle tip and at the tip. Moderate elevation of the local temperature in and around the tumor may even be a desirable effect. It has been observed that the elevation OS temperature increases the radiosensitivity of tumors; after one hour of heating at 43"C, the radiosensitivity of certain tumors has increased by factors of 3 to 4 [SI. Thus, the heat generated by the pINRT technique may be useful in enhancing its effectiveness.
Accelerator Technologies
The development of smaller, more efficient radiation sources has been one result of the technological advances of the last decade. Compact radio frequency quadrupoles, h e a r accelerators, and tandem accelerator systems have been designed and built for purposes ranging &om explosives detection in luggage [9] , to rocket-borne strategic defense, to radioisotope production for use in applications, the RFQ can be designed to have high transmission, low rfpower and relatively short length, even for MeV output energies, if a high operating frequency is used. These characteristics have been exploited in the design of a compact linac system for proton radiotherapy using low energy 3He ion induced nuclear reactions. This compact system is capable of delivering 10 pA of 3He" ion beam at 800
* keV output energy with a beam spot diameter of 1 mm. It is only 60 cm in length and requires an input ac power of only 1500 watts. At the cost of higher power consumption, the siime system can be used to deliver up to 1 milliamp at 800 keV with a beam spot diameter of 2 cm.
Because MRT needs only a fixed output energy, the RFQ system offers several advantages for this application. It is simple to operate, and produces no radiation during its operation because of the low rf power is fed through the vacuum chamber into the resonator using a coaxial cable that also goes through this end flange. The accelerator and injector are pumped by a turbomolecular pump that is mounted on the chamber through a flanged port. The cooling for the ion source and RFQ resonator is provided by a selfcontained cooling system mounted within the electronics cabinet. The vacuum controls and roughing system are also mounted in the cabinet, which is a standard double bay cabinet of six foot height.
All of the remaining support electronics, including the rf power amplifier to drive the RFQ, are located within the electronics cabinet. This cabinet contains an isolated high voltage deck for the ion source power supplies and gas input system, the high voltage power supplies for the ion source, einzel lens and rf amplifier, and the control system. The cabinet is powered from a single 1 lOV, single phase input at 20A maximum current and has a gross weight of less than 1500 Ib. In this application, the accelerator is designed to be used remotely from the cabinet and can be mounted in any orientation. The accelerator is
. connected to the cabinet through a five inch diameter, flexible umbilical cablr: for all power and cooling.
Similarly, the control computer and monitor can be connected remotely to the cabinet through a single twisted pair cable from the rack monitor and interface chassis.
The PC-based control system has two levels of operation. For routine operation, the high level enables even an unskilled operator to run the MRT RFQ with a fixed parameter configuration using only a few function keys. The individual control loops and accelerator diagnostics are available at the lower level, allowing a trained technician to optimize the beam parameters and change the beam pulsing characteristics.
The output beam has a diameter of 1.1. mm, but can be focused to 8 parallel beam of 1.0 mm diameter or it can be expanded to be 2.0 cm in diameter by using no focusing magnets. This makes the MRT RFQ ideally suited for use in either JIINRT or Topical INRT. AccSys Technology, Inc. has also constructed a deuterium-beam RFQ accelerator, the Model DL-1 Linac [15] , with a deuterium ion beam output of 6-8 milliamps; this model could serve as a deuterium producing accelerator for the inverse nuclear reaction.
ii. Nested High Voltage Generator
The Nested High Voltage Generator (NHVG) is a compact DC accelerator technology which is well suited to the generation of ion beams in a "tandem" configuration. In an MRT tandem accelerator, a beam of positive 'He ions is generated by a duoplasmatron ion source. These ions traverse a low density gas cell where a fraction of the ions (a few percent) undergo charge exchange to become negative ions. These ions are accelerated to an energy of 400 keV in the center of the accelerator. At that point, they strike a thin carbon foil which "strips" electrons from the negative ion, and it once again becomes a positive ion. The ion, having changed sign is now accelerated to ground potential through the second half of the tandem column. Some of the ions are actually doubly charged, and the beam which reaches ground potential consists of 800 keV and 1200 keV ions (minus 50 -100 kV lost in the stripping foil).
The tandem accelerator must both produce voltage and insulate that voltage. The NHVG has a very small diameter, (less than Deuterated target disks were fabridated for each o f the selected tube diameters using the following procedure. Appropriately sized disks for each tube size were punched from .001" ( 2 5~) and .005" (127~)
stainless steel foils and mounted in an electron-beam evaporator with a base pressure of IxIO" Torr. The substrate disks were heated to 350 "C until the chamber pressure recovered to better than 1x108 Torr.
With deposition blocked by a shutter, the evaporator source was heated until the pressure recovered to better than IxIO-' Torr. The shutter protecting the stainless steel disks was then retracted and a 5 micron of zirconium layer was deposited onto the disks; the circumference of each disk, which is later welded to the stainless steel tube, was masked to preserve a clean welding "lip". After deposition, the source was turned
. off and the pressure allowed to recover to 1x108 Torr. The zirconium-deposited disks were then heated to 500 OC for 15 minutes and then cooled to 350 "C. At this temperature, the evaporation chamber was backfilled with 10 Torr of deuterium gas for 15 minutes, after which the chamber was evacuated, the sample cooled, and removed. Measurements using the D('He,a)H deuterium profiling technique indicate typical stoichiometries of ZrD1~9.1~95. Finally the deuterated discs were electron beam welded to the stainless steel needle stock with the deuterated layer facing inward. The needle is inserted into a swaged fitting that is welded into a 2.75" Conflat flange which, in turn, is mounted on the beamline of the EN Tandem Van de Graaf accelerator which provided the 'He beams used for the radiation dose measurements. Freestanding thin metal zirconium foils (=5p) mounted in stainless steel frames are comniercially available [20] and would be a suitable replacement for the evaporated films used here.
i. @NRT
Radiation therapy is an effective treatment of neoplasms [21, 22] . The goals of all modes of radiation therapy are to kill tumor cells and to minimize complications in the surrounding normal tissue. However, the utility of radiation therapy is limited by the difference between the radiosensitivity of the cancer cells and that of the surrounding normal tissues, since radiotherapy is most commonly administered via an external beam [23] . Complications of radiotherapy are defined as symptoms caused by death of normal tissue in the path of the beam. Curves relating the radiation dose to the probability of tissue death for either tumor tissue or nearby normal tissue are described in figure 6 . The curve describing the probability of tumor tissue death represents the probability for cure of the tumor, while the probability of normal tissue dezth relates to the incidence of complications. Strategies for delivery of radiation therapy manipulate many factors in an attempt to maximize the separation of these two curves. This will maximize tumor control while minimizing complications for any specific dose level.
The strategies employed to minimize complications include manipulation of the size of each dose fraction, the treatment volume, the time between each fraction, and the total number of Grays of radiation administered. The complications result fiom the need to treat a tumor through normal tissue. Because radiotherapy is usually administered as an external beam, the field of tissue radiated includes the tissue between the radiation source and the tumor, the tumor itself and the tissue in the path of the beam but distal to the tumor. MRT has been developed to bypass the radiation effect on normal tissue that surrounds tumor tissue. By limiting the field of tissue receiving radiation and avoiding radiating normal tissue, much higher doses of radiation therapy can be given, ensuring that the tumor is eradicated, yet complications are minimized. These doses can be high enough that they are destructive to all tissues. With MRT the radiation field is small and can be precisely placed without the need for transmitting it through norma1 tissues, and the higher doses are absorbed almost exclusively by the tumor tissue. Also, for these reasons larger fractions can be given. This allows a tumor to be treated in a smaller number of fractions than with external beam radiation therapy (EBRT).
The prospective internal uses of INRT can be broken down into three broad categories: Treatment of tumors in difficult to reach areas; treatment of tumors that are situated near structures that are easily damaged by radiation therapy or surgery; and treatment of surgical margins. Tumors often occur in organs in which it is difficult to operate. The difficulties may be because the surgical approach is hazardous or because surgery on a particular organ is technically difficult. Although tumors often occur in tht: brain, the vast majority are situated deep in the parenchyma and not on the surface [24, 25] . These tumors are not easy to resect because all the intervening brain tissue between the surface of the brain and the mass to be resected will be disrupted by the surgical approach. Similarly, all brain tissue in the path of external beam radiotherapy will be affected by the treatment.
These tumors can easily be biopsied using a stereotactic CT guided needle [24, 25, 26] . This allows a needle to be placed into an intracranial mass according to coordinates calculated fiom a pre-determined h e of reference. When the needle is passed into the mass, cells can be withdrawn to be analyzed by a pathologist.
At this point, a second needle with a deuterated tip can be inserted into the mass and the lesion can be ablated using JNRT. Because this approach is minimally invasive (a single burr hole though the skull followed by sequential passes with two different needles along the same line) the disruption to the brain is markedly reduced.
Early tumors of the kidney occupy the other end of the spectrum. The kidney has such a high blood flow rate that surgery on it is very difficult. If an attempt is made to remove only a portion of the kidney the intraoperative blood loss is very high, and the post-operative course has a high coinplication rate secondary to delayed bleeding [27,28 3. Because of this, the usual treatment of a renal mass is removal of the entire kidney, which is a much safer procedure. With MRT the deuterated needle tip can be inserted into the mass percutaneously (through the skin, without any incision), the placement of the needle can be confirmed by ultrasound or CT scan then the mass can be treated with INRT. If the mass is larger than the treatment volume provided by INRT, this procedure can be employed repetitively. These treatments may be either at the same setting or serially, Other locations where these strategies can be employed include the thyroid and the lung.
The second category consists of tumors that have occurred near structures that would be no longer finctional after surgery or EBRT, such as the eye or the vocal cords. Tumors of the vocal cords are readily cured by both surgery and EBRT [29] , however the EBRT standard field is a 6x6 cm2 area with all the attendant morbidity of radiating the skin, the entire larynx, a' portion of the pharynx and cervical spinal cord that corresponds to the 6x6 cm2 port. This can be avoided by using INRT. A needle can be placed on the lesion through an endoscope inserted through the mouth. The lesion can then be treated. It is unclear how the larynx will react to a single tumoricidal dose of INRT or if multiple smaller hctions will have to be administered. Those clinical studies will have to be performed to determine the normal tissue tolerance. . radiation producing equipment.
Conclusions
The concept of utilizing low energy, ion-induced nuclear reactions to produce radiation suitable for radiotherapy purposes has been described. One implementation of this concept, using the 650 keV d?He,~)~He nuclear reaction, has been detailed with respect to the design and fabrication of the deuterated needle tips which, used in conjunction with a 3He ion beam, produce 17.4 MeV proton radiation. The radiation dose patterns achievable with both an internal point-source and an external topical exposure have been calculated using a computer simulation incorporating the l/r2 and Bragg peak effects on the delivered dose; comparison to experiment verifies the simulation. Thermal effects arising from internal use, as well as the design and availability of suitably compact, commercial ion accelerators and ion sources are also examined. Lastly, potential clinical applications of such a source of radiation have been commented on.
Developments in radiation therapy have historically stressed increasing dose control and localization of radiation damage. Advances in the design of novel radiation producing equipment, radiation delivery, and research in manipulating the radiosensitivity of tissue through chemical, thermal and other means will likely contribute to improved tailoring of the delivery of radiation damage. The use of low energy, nuclear reactions to produce highly localized, therapeutic radiation utilizing relatively inexpensive, compact, lowenergy ion accelerators may contribute to specific modes of treatment. Moreover, the small size, reduced power requirements and support facilities of this technique make it conducive to use in the medical office or operating theater and may also provide efficient radiotherapy capabilities, (especially for melanomas), to the large Third World community which has a great need for affordable radiation treatment facilities.
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Figure Captions
1. Energy deposition versus depth for several forms of radiation. Electron beams and x-rays display a broad region of energy deposition in which significant damage to healthy tissue can occur. High energy proton and deuteron beams, incident from outside the body, display sharp end-of-range damage peaks, but also do significant damage to healthy tissue along the incident path. 17.4 MeV protons, created at the site of the tumor using low energy, ion-induced nuclear reactions, irradiate a much more localized volume. An evacuated needle delivers the low energy ion beam to the site of the tumor, avoiding any radiation damage to healthy tissue. 
4.
Comparison of computer calculated dose and the measured energy deposition of protons produced by an INRT needle in a water target. The range of the MRT protons is reduced from 3.1 mm due to additional energy losses in the detector's surface metallization layer and waterproofing shroud.
5.
Tissue heating induced by plNRT. Time-dependent temperature profiles are shown for positions 0, 3, and 5 millimeters away from the needle tip during a 100 second pMRT exposure using an incident 1 pA, 800 keV 'He ion beam.
6. Dose-response curves for control of a hypothetical tumor and for normal tissue damage. Treatment to dose level 1 results in a 90% probability of cure and 10% probability of complications. Because of the shape of the sigmoid response curves, if the dose is increased to level 2, the control rate increases by only 5% but the rate of complications increases more dramatically to 28%. The actual separation between the two curves will vary for different treatment regimens and tumors types.
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